Core Viewpoint - Pfizer Inc. recommends shareholders reject the unsolicited mini-tender offer from Tutanota LLC, which proposes to purchase up to 1 million shares at $32.00 per share, as the offer price is below the market value and contingent on conditions that may not be met [1][2][3]. Offer Details - Tutanota's offer is for approximately 0.02% of Pfizer's outstanding shares as of March 9, 2026, and is conditioned on Pfizer's stock price exceeding $32.00 on the last trading day before the offer expires [1][2]. - The offer is set to expire at 5:00 p.m. on April 13, 2026, but Tutanota may extend this period at its discretion [2][6]. Shareholder Guidance - Pfizer advises shareholders not to tender their shares due to the conditions attached to Tutanota's offer, including the requirement for Tutanota to secure financing, which it currently lacks [2][6]. - Shareholders who have already tendered their shares can withdraw them prior to the expiration date [2][6]. Regulatory Context - Mini-tender offers like Tutanota's seek to acquire less than 5% of a company's shares, allowing them to bypass many SEC disclosure requirements, which may result in less protection for investors [4][5]. - The SEC has warned that some mini-tender offers at below-market prices may catch investors off guard if they do not compare the offer price to the current market price [5].

Financial Performance - Q3 2025 revenues were $16.7 billion, a 7% decrease compared to Q3 2024, primarily due to a decline in COVID-19 product revenues[37] - Adjusted diluted EPS for Q3 2025 was $0.87, a 16% decrease compared to $1.06 in Q3 2024, impacted by a $1.35 billion Acquired In-Process R&D charge related to the 3SBio licensing agreement[37] - The company reaffirms its 2025 revenue guidance of $61.0 to $64.0 billion and raises and narrows its adjusted diluted EPS range to $3.00 to $3.15[47] Strategic Initiatives - The company reached an agreement with the U S Government to provide greater clarity and reduce uncertainty around tariffs and pricing[7, 8] - The company proposed acquisition of Metsera to accelerate and expand presence in obesity with highly differentiated medicines[7, 8] - The company closed of 3SBio Licensing Agreement, which is a potential foundational backbone in the company's Oncology portfolio[7, 8] Pipeline Development - PADCEV + pembro significantly and meaningfully improved overall and event-free survival vs surgery alone[11] - Single Arm Phase 2 PHAROS Trial OS showed 67% at 49 months, 54% at 47 months, 49% at 45 months[13] - XTANDI + Leuprolide showed HR (95% CI): 0.597 (0.444-0.804) P = 0.0006[17] Cost Management - The company expects $7.2 billion in total net cost savings by the end of 2027 while also reinvesting $500 million to strengthen R&D productivity[43]